These observations point to critical questions for further clinical development of anti-CTLA-4 regarding the cellular and molecular mechanisms involved in the anti-tumor effects, the characteristics that distinguish responders from non-responders, and the best combination strategies to improve cancer outcomes. Here, CTLA4 is linked to neoplasm.